Market-wide clinical trial search
/api/v1/public/clinical-trialsSearch the full universe of clinical trials across every tracked company (cross-company), not scoped to a single ticker. Filter by phase, indication/condition, sponsor, status, and a date window on a chosen date field, then sort and paginate. Trial data is sourced from ClinicalTrials.gov. This is an alias of `/clinical-trials/search` — both paths behave identically.
Parameters
Query
Phase filter. CSV of phase tokens — e.g. 'PHASE2,PHASE3', '2,3', or 'Phase 2'. Alias: `phases`.
Condition / indication filter. CSV of exact condition strings (case-sensitive). Alias: `conditions`.
Sponsor name, case-insensitive substring match.
Exact trial status (e.g. 'RECRUITING', 'ACTIVE_NOT_RECRUITING', 'COMPLETED').
Date column the from/to range applies to.
Inclusive lower date bound (partial-ISO ok). Alias: `dateFrom`.
Inclusive upper date bound (partial-ISO ok). Alias: `dateTo`.
Sort column (a whitelisted date column or updated_at).
Sort direction.
Page size (1-200, default 50).
Number of results to skip (default 0)
Code example
curl -X GET 'https://api.signal8.ai/api/v1/public/clinical-trials?from=2024-01-01&to=2024-12-31&limit=10&offset=0' \
-H "X-Api-Key: $SIGNAL8_API_KEY"Request URL
https://api.signal8.ai/api/v1/public/clinical-trials?from=2024-01-01&to=2024-12-31&limit=10&offset=0{
"data": {
"trials": [
{
"id": "ct-NCT03682068",
"type": "clinical_trial",
"ticker": "AZN",
"date": "2026-05-27",
"title": "Study of Durvalumab Given With Chemotherapy in Patients With Unresectable Urothelial Cancer",
"description": "Phase 3 | Active Not Recruiting | Unresectable Locally Advanced Urothelial Cancer, Metastatic Urothelial Cancer",
"metadata": {
"nctId": "NCT03682068",
"status": "ACTIVE_NOT_RECRUITING",
"phases": [
"PHASE3"
],
"conditions": [
"Unresectable Locally Advanced Urothelial Cancer",
"Metastatic Urothelial Cancer"
],
"interventions": [
{
"name": "Durvalumab",
"type": "DRUG"
},
{
"name": "Tremelimumab",
"type": "DRUG"
}
],
"enrollment": 1246,
"enrollmentType": "ACTUAL",
"sponsor": "AstraZeneca",
"studyType": "INTERVENTIONAL",
"startDate": "2018-09-27",
"completionDate": "2027-06-01",
"primaryCompletionDate": "2026-06-01",
"hasResults": false
}
},
{
"id": "ct-NCT05217446",
"type": "clinical_trial",
"ticker": "PFE",
"date": "2026-04-06",
"title": "Encorafenib Plus Cetuximab With Pembrolizumab in Previously Untreated Metastatic Colorectal Cancer",
"description": "Phase 2 | Active Not Recruiting | Metastatic Colorectal Cancer",
"metadata": {
"nctId": "NCT05217446",
"status": "ACTIVE_NOT_RECRUITING",
"phases": [
"PHASE2"
],
"conditions": [
"Metastatic Colorectal Cancer"
],
"interventions": [
{
"name": "Encorafenib",
"type": "DRUG"
},
{
"name": "Cetuximab",
"type": "BIOLOGICAL"
},
{
"name": "Pembrolizumab",
"type": "BIOLOGICAL"
}
],
"enrollment": 107,
"enrollmentType": "ACTUAL",
"sponsor": "Pfizer",
"studyType": "INTERVENTIONAL",
"startDate": "2022-03-15",
"completionDate": "2027-02-28",
"primaryCompletionDate": "2026-09-30",
"hasResults": false
}
}
],
"pagination": {
"total": 184,
"limit": 50,
"offset": 0,
"hasMore": true
}
}
}